STOK Logo

Stoke Therapeutics, Inc. (STOK) 

NASDAQ
Market Cap
$601.71M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
726 of 774
Rank in Industry
400 of 432

Largest Insider Buys in Sector

STOK Stock Price History Chart

STOK Stock Performance

About Stoke Therapeutics, Inc.

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the …

Insider Activity of Stoke Therapeutics, Inc.

Over the last 12 months, insiders at Stoke Therapeutics, Inc. have bought $0 and sold $72.86M worth of Stoke Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Stoke Therapeutics, Inc. have bought $29.25M and sold $19.01M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 375,000 shares for transaction amount of $14.63M was made by Harrison Seth Loring () on 2020‑11‑24.

List of Insider Buy and Sell Transactions, Stoke Therapeutics, Inc.

2024-11-01SaleCHIEF MEDICAL OFFICER
10,000
0.0187%
$12.68$126,803+3.19%
2024-10-01SaleCHIEF MEDICAL OFFICER
10,000
0.0187%
$12.06$120,648+1.70%
2024-09-19Sale10 percent owner
1.94M
3.4152%
$14.05$27.22M-17.17%
2024-09-03SaleCHIEF MEDICAL OFFICER
10,000
0.0189%
$14.95$149,481-13.31%
2024-08-01SaleCHIEF MEDICAL OFFICER
10,000
0.019%
$14.58$145,843-6.86%
2024-07-02SaleChief Business Officer
2,500
0.0049%
$13.11$32,7790.00%
2024-07-01SaleCHIEF MEDICAL OFFICER
10,000
0.0204%
$13.75$137,4580.00%
2024-06-03SaleCHIEF MEDICAL OFFICER
10,000
0.0189%
$15.22$152,185-10.10%
2024-05-20SaleCEO
42,350
0.0779%
$15.43$653,529-12.72%
2024-05-20SaleGENERAL COUNSEL & CORP SEC
8,599
0.0154%
$15.04$129,327-12.72%
2024-05-20SaleCOO & CBO
50,000
0.0917%
$15.39$769,500-12.72%
2024-05-01SaleCHIEF MEDICAL OFFICER
10,000
0.0189%
$11.37$113,653+20.14%
2024-04-17Sale10 percent owner
3.6M
6.8708%
$11.60$41.76M+17.45%
2024-04-01SaleCHIEF MEDICAL OFFICER
9,426
0.02%
$13.23$124,684+1.63%
2024-04-01SaleCOO & CBO
61,329
0.1299%
$13.23$811,212+1.63%
2024-03-28SaleGENERAL COUNSEL & CORP SEC
5,126
0.0108%
$13.20$67,668+1.56%
2024-03-19SaleCEO
11,150
0.0263%
$6.10$67,999+136.14%
2024-03-19SaleCFO
4,116
0.0097%
$6.10$25,102+136.14%
2024-03-19SaleCHIEF MEDICAL OFFICER
4,116
0.0097%
$6.10$25,102+136.14%
2024-03-19SaleCOO & CBO
4,116
0.0097%
$6.10$25,102+136.14%

Insider Historical Profitability

<0.0001%
Harrison Seth Loring
17161713
32.4008%
$11.3620<0.0001%
Apple Tree Partners IV, L.P.10 percent owner
17161713
32.4008%
$11.3620<0.0001%
RTW INVESTMENTS, LP10 percent owner
3544248
6.6914%
$11.3661<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Skorpios Trust$194.99M27.7114.44M0%+$099.92
Redmile Group$68.49M9.735.07M+93.22%+$33.04M0.7
RTW Investments, LP$57.04M8.114.22M+2.27%+$1.27M0.85
Morgan Stanley$54.34M7.724.03M+19.42%+$8.84M<0.01
BlackRock$52.09M7.43.86M+87.28%+$24.28M<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.